# US 2005/0032869 A1 · Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0032869 A1
- Document ID: US20050032869A1
- Status: Published application
- Kind: A1
- Application number: 10/882,492
- Filed: 2004-07-01
- Published: 2005-02-10
- Earliest claimed: 2003-07-08
- Assignees: Pharmacia Italia S.p.A.
- Inventors: Daniela Berta; Barbara Forte; Sergio Mantegani; Mario Varasi; Paola Vianello
- Web page: https://patentgrep.com/patent/US20050032869A1

## CPC

- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- A61K 31/416: condensed with carbocyclic ring systems, e.g. indazole
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/08: of the prostate
- A61P 13/12: of the kidneys
- A61P 17/06: Antipsoriatics
- A61P 17/14: for baldness or alopecia
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/14: containing three or more hetero rings
- C07D 403/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Pyrazolyl-indole derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

## Claims

### Claim 1

A method for treating diseases caused by and/or associated with an altered protein kinase activity, by administering to a mammal in need thereof an effective amount of a compound of formula (I)
wherein
R is hydrogen, halogen, nitro, cyano, hydroxy, or it is a group optionally further substituted selected from straight or branched C1-C6 alkyl or C1-C6 alkoxy, C3-C6 cycloalkyl, aryl, heterocyclyl, or it is a group —NR′R″, —CONR′R″, —NR′COR″, —COOR′ or —SO2NR′R″, wherein R′ and R″ are, the same or different and independently in each occasion, a hydrogen atom or a group optionally further substituted selected from straight or branched C1-C6 alkyl, C3-C6 cycloalkyl, aryl or heterocyclyl; or, taken together with the nitrogen atom to which they are attached, R′ and R″ may form a 5 or 6 membered nitrogen containing heterocycle, optionally comprising one additional heteroatom selected among N, O or S;
R1 has the meanings above reported to r but other than hydroxy;
m is an integer from 1 to 4;
n is 1 or 2;
and the pharmaceutically acceptable salts thereof.

### Claim 2 (depends on 1)

The method according to claim 1 wherein the disease is a cell proliferative disorder selected from the group consisting of cancer, Alzheimer's disease, viral infections, autoimmune diseases and neurodegenerative disorders.

### Claim 3 (depends on 2)

The method according to claim 2 wherein the cancer is selected from the group consisting of carcinoma, squamous cell carcinoma, hematopoietic tumors of myeloid or lymphoid lineage, tumors of mesenchymal origin, tumors of the central and peripheral nervous system, melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid follicular cancer, and Kaposi's sarcoma.

### Claim 4 (depends on 2)

The method according to claim 2 wherein the cell proliferative disorder is selected from the group consisting of benign prostate hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis, glomerulonephritis and post-surgical stenosis and restenosis.

### Claim 5 (depends on 1)

The method according to claim 1 which provides tumor angiogenesis and metastasis inhibition as well as treatment of organ transplant rejection and host versus graft disease.

### Claim 6 (depends on 1)

The method according to claim 1 which provides treatment or prevention of radiotherapy-induced or chemotherapy-induced alopecia.

### Claim 7 (depends on 1)

The method according to claim 1 further comprising subjecting the mammal in need thereof to a radiation therapy or chemotherapy regimen in combination with at least one cytostatic or cytotoxic agent.

### Claim 8 (depends on 1)

The method according to claim 1 wherein the mammal in need thereof is a human.

### Claim 9 (depends on 1)

A method for inhibiting protein kinase activity which comprises contacting the said protein kinase with an effective amount of a compound of formula (I) as defined in claim 1.

### Claim 10

A compound of formula (I)
wherein
R is hydrogen, halogen, nitro, cyano, hydroxy, or it is a group optionally further substituted selected from straight or branched C1-C6 alkyl or C1-C6 alkoxy, C3-C6 cycloalkyl, aryl, heterocyclyl, or it is a group —NR′R″, —CONR′R″, —NR′COR″, —COOR′ or
—SO2NR′R″, wherein R′ and R″ are, the same or different and independently in each occasion, a hydrogen atom or a group optionally further substituted selected from straight or branched C1-C6 alkyl, C3-C6 cycloalkyl, aryl or heterocyclyl; or, taken together with the nitrogen atom to which they are attached, R′ and R″ may form a 5 or 6 membered nitrogen containing heterocycle, optionally comprising one additional heteroatom selected among N, O or S;
R1 has the meanings above reported to R but other than hydroxy;
m is an integer from 1 to 4;
n is 1 or 2;
and the pharmaceutically acceptable salts thereof.

### Claim 11 (depends on 10)

A compound of formula (I) according to claim 10 wherein R is a hydrogen or halogen atom, R1 is a hydrogen atom or a group selected from cyano, —COOR′ or —CONR′R″, wherein R′ and R″ are as defined in claim 10, and m and n are both 1.

### Claim 12 (depends on 10)

A compound of formula (I) according to claim 10 wherein R is a group —COOR′ or —CONR′R″, wherein R′ and R″ are as defined in claim 10, R1 is hydrogen, and m and n are both 1.

### Claim 13 (depends on 10)

A compound of formula (I) according to claim 10 wherein the optional substituents to any one of the groups R, R1, R′ and R″ is selected from: halogen, nitro, oxo groups (═O), carboxy, cyano, alkyl, perfluorinated alkyl, hydroxyalkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, amino groups and derivatives thereof such as alkylamino, dialkylamino, cycloalkylamino, arylamino, diarylamino, arylalkylamino, ureido, alkylureido or arylureido; carbonylamino groups and derivatives thereof such as formylamino, alkylcarbonylamino, alkenylcarbonylamino, arylcarbonylamino, alkoxycarbonylamino; hydroxy groups and derivatives thereof such as alkoxy, aryloxy, heterocyclyloxy, alkylcarbonyloxy, arylcarbonyloxy, cycloalkenyloxy or alkylideneaminooxy; carbonyl groups and derivatives thereof such as alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, cycloalkyloxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl; sulfurated derivatives such as alkylthio, arylthio, alkylsulfonyl, arylsulfonyl, alkylsulfinyl, arylsulfinyl, aryisulfonyloxy, aminosulfonyl, alkylaminosulfonyl or dialkylaminosulfonyl.

### Claim 14 (depends on 10)

Any specific compound of formula (I) according to claim 10, optionally in the form of a pharmaceutically acceptable salt, as per the list provided in example 18.

### Claim 15 (depends on 10)

A process for preparing the compounds of formula (I) and the pharmaceutically acceptable salts, according to claim 10, which process comprises:
a) coupling, in the presence of a suitable catalyst, the compound of formula (II) with the compound of formula (III)
wherein R, R1, m and n are as defined in claim 10; Q and Q′, the same or different from each other, may represent suitable nitrogen protective groups or polymeric solid supports; X is a halogen atom or a group selected from methylsulfonyloxy, trifluoromethylsulfonyloxy, phenylsulfonyloxy or fluorido-sulphate (—OSO2F); and Z is selected from halogen, boronic acid, boronate, trialkyl-stannane, trihalostannane, zinc halide, cuprate, alkyldihalo-sylane or a Grignard salt; so as to obtain a compound of formula (IV)
b) optionally converting the compound of formula (IV) into another compound of formula (IV); and
c) deprotecting or cleaving from the resin Q and Q′ the compound of formula (IV), so as to obtain the compound of formula (I) and, whenever desired, converting it into a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 15)

The process of claim 15 wherein the catalyst, in step (a), is selected from tetrakis(triphenylphosphine)palladium, tris(dibenzylideneacetone)dipalladium, palladium chloride, bis(triphenylphosphine)palladium chloride, palladium acetate, nickel chloride, 1,2-bis (diphenylphosphino) ethane nickel chloride, dichlorobis(tributylphosphine)nickel, nickel acetylacetonate and of a suitable ligand such as triphenylphosphine, tri-2-furylphosphine, tributylphosphine, 2-dicyclohexylphosphino-2′-(n,n-dimethylamino)biphenyl, triphenylarsine.

### Claim 17 (depends on 15)

The process of claim 15 wherein, within the compounds of formula (II) and (III), X is a iodine atom and Z is a boronic acid [—B(OH)2] or tributyl stannane.

### Claim 18 (depends on 15)

The process of claim 15 wherein Q and Q′, as nitrogen protecting groups, are each independently selected from trityl, trimethylsilylethoxymethyl (SEM), tert-butoxycarbonyl (boc), ethylcarbamate or trichloroethylcarbamate.

### Claim 19 (depends on 15)

The process of claim 15 wherein Q and Q′, as suitable polymeric supports, are each independently selected from trityl resin, chloro-trityl resin, methylisocyanate resin, p-nitrophenyl carbonate Wang resin or isocyanate polystyrenic resin.

### Claim 20 (depends on 10)

A process for preparing the compounds of formula (I) and the pharmaceutically acceptable salts, according to claim 10, which process comprises:
d) reacting an hydrazine derivative of formula (V) with a pyrazole derivative of formula (VI)
wherein R, R1, m and n are as defined in claim 10, so as to obtain a compound of formula (VIl)
e) reacting the compound of formula (VIl) under acidic conditions and in the presence of a Lewis acid, so as to obtain a compound of formula (I); and,
f) optionally converting it into another compound of formula (I) and/or into a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 21)

The process of claim 21 wherein, in step (e), the Lewis acid is selected from zinc chloride, boron trifluoride, triethylaluminum or trifluoroacetic anhydride.

### Claim 22

A library of two or more compounds of formula (I)
wherein
R is hydrogen, halogen, nitro, cyano, hydroxy, or it is a group optionally further substituted selected from straight or branched C1-C6 alkyl or C1-C6 alkoxy, C3-C6 cycloalkyl, aryl, heterocyclyl, or it is a group —NR′R″, —CONR′R″, —NR′COR″, —COOR′ or —SO2NR′R″, wherein R′ and R″ are, the same or different and independently in each occasion, a hydrogen atom or a group optionally further substituted selected from straight or branched C1-C6 alkyl, C3-C6 cycloalkyl, aryl or heterocyclyl; or, taken together with the nitrogen atom to which they are attached, R′ and R″ may form a 5 or 6 membered nitrogen containing heterocycle, optionally comprising one additional heteroatom selected among N, O or S;
R1 has the meanings above reported to R but other than hydroxy;
m is an integer from 1 to 4;
n is 1 or 2;
and the pharmaceutically acceptable salts thereof.

### Claim 23 (depends on 10)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I), as defined in claim 10, and at least one pharmaceutically acceptable excipient, carrier and/or diluent.

### Claim 24 (depends on 23)

A pharmaceutical composition according to claim 23 further comprising one or more chemotherapeutic agents.

### Claim 25 (depends on 10, 23)

A product or kit comprising a compound of formula (I) as defined in claim 10 or a pharmaceutical compositions thereof as defined in claim 23, and one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.

### Claim 26 (depends on 10)

A compound of formula (I) as defined in claim 10 for use as a medicament.

### Claim 27 (depends on 10)

Use of a compound of formula (I) as defined in claim 10 in the manufacture of a medicament with antitumor activity.
